Find Clinical Trials for Leukemia

Paid Clinical Trials and Focus Groups by Category

All Categories ... Medical Conditions » ... Cancers » ... Leukemia

A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

Condition: Acute Myelogenous Leukemia
Intervention: Drug: clofarabine
Sponsor: Genzyme
Recruiting - verified February 2010
Genomic Changes in Childhood Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Intervention:
Sponsor: National Taiwan University Hospital
Not yet recruiting - verified March 2010
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Condition: Leukemia
Intervention: Drug: Bendamustine
Sponsor: Cephalon
Not yet recruiting - verified March 2010
Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment

Conditions: Hairy Cell Leukemia (HCL); Chronic Lymphocytic Leukemia (CLL); Non-Hodgkins Lymphoma (NHL); Cutaneous T Cell Lymphoma (CTCL); Adult T Cell Lymphoma (ATL)
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Study to Investigate CAL-101 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine
Sponsor: Calistoga Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010
A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Non-Hodgkin's Lymphoma (NHL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL)
Intervention: Drug: CAT-8015
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Standard Chemotherapy With or Without Nelarabine or Epratuzumab and/or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Conditions: Leukemia; Mucositis; Oral Complications
Interventions: Biological: epratuzumab; Biological: palifermin; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Radiation: total-body irradiation
Sponsor: University College London Hospitals
Recruiting - verified March 2010
A Study of ABT-263 in Combination With Rituximab in Previously Untreated Patients With B Cell, Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: rituximab
Sponsors: Genentech; Abbott
Not yet recruiting - verified March 2010
A Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Conditions: Leukemia, Myelogenous, Acute; Myelodysplastic Syndromes
Intervention: Drug: Oxi4503
Sponsor: University of Florida
Not yet recruiting - verified March 2010
Azacitidine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified March 2010
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Condition: Mucositis
Intervention: Drug: Doxycycline hyclate
Sponsors: Metropolitan Autonomous University; Instituto Nacional de Cancerologia de Mexico
Not yet recruiting - verified March 2010
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

Condition: Chronic Lymphocytic Leukemia
Intervention:
Sponsor: Celgene Corporation
Not yet recruiting - verified March 2010
Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Intervention:
Sponsor: Samsung Medical Center
Recruiting - verified March 2010
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified February 2010
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

Conditions: Cancer Survivor; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Testicular Germ Cell Tumor
Interventions: Genetic: DNA analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: gene mapping; Genetic: loss of heterozygosity analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: rituximab; Drug: alvocidib; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Drug: ofatumumab 100 mg, 1000 mg / vial
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Disease, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: plerixafor; Biological: filgrastim; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified February 2010
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-Cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: everolimus; Drug: lenalidomide; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: fluorescence in situ hybridization
Sponsor: Mayo Clinic
Not yet recruiting - verified February 2010
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Condition: Chronic Myeloid Leukemia
Intervention: Other: Discontinuation of therapy
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsor: Celgene Corporation
Not yet recruiting - verified February 2010
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib; Drug: belinostat; Other: laboratory biomarker analysis; Genetic: western blotting; Other: pharmacological study; Other: flow cytometry
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Intervention: Other: No Intervention
Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting - verified February 2010
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogenic Stem Cell Transplantation

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Intervention: Drug: Plerixafor
Sponsor: St. Jude Children's Research Hospital
Not yet recruiting - verified March 2010
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML and Ph+ ALL Patients

Conditions: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: Gleevec/Glivec
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified February 2010
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia

Condition: Lymphocytic Leukemia, Chronic
Intervention: Drug: rituxan [rituximab]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Biomarker Expression in Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin; Drug: Rituximab; Drug: Bendamustine
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Graft Versus Host Disease; Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: rituximab; Drug: mycophenolate mofetil; Drug: tacrolimus; Drug: anti-thymocyte globulin; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: busulfan; Radiation: total-body irradiation; Biological: graft-versus-tumor induction therapy; Biological: immunosuppressive therapy
Sponsor: University of Nebraska
Recruiting - verified March 2010
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified December 2009
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: AS1411; Drug: Cytarabine
Sponsor: Antisoma Research
Recruiting - verified March 2010
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Condition: WT1-positive Acute Myeloid Leukemia
Intervention: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Plerixafor; Drug: Mitoxantrone; Drug: Etoposide; Drug: Cytarabine
Sponsor: Washington University School of Medicine
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Hematopoietic/Lymphoid Cancer; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Drug: cyclophosphamide; Biological: ofatumumab; Procedure: laboratory biomarker analysis; Other: flow cytometry; Genetic: protein expression analysis
Sponsor: Mayo Clinic
Recruiting - verified February 2010
A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-263

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors
Interventions: Drug: ABT-263; Drug: Ketoconazole
Sponsor: Abbott
Recruiting - verified January 2010
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Condition: Leukemia
Intervention: Drug: AEG35156
Sponsor: Aegera Therapeutics
Recruiting - verified February 2010
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified November 2009
Donor Lymphocytes in Preventing and Treating Cytomegalovirus Infection or Adenovirus Infection in Patients Who Have Undergone Umbilical Cord Blood Transplant

Condition: Cancer
Interventions: Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes; Other: laboratory biomarker analysis
Sponsors: Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified December 2009
A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified February 2010
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: chemotherapy; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: examination; Procedure: management of therapy complications
Sponsor: Ziekenhuis Netwerk Antwerpen Middelheim
Recruiting - verified October 2009
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomide
Sponsors: Roswell Park Cancer Institute; Celgene Corporation
Recruiting - verified March 2010
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
Sponsors: Georgetown University; GlaxoSmithKline; Cephalon
Not yet recruiting - verified March 2010
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine and Bexarotene; Drug: Decitabine and Bexarotene; Drug: Decitabine and Bexarotene
Sponsor: Washington University School of Medicine
Recruiting - verified March 2010
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors
Interventions: Drug: ABT-263; Drug: erlotinib; Drug: irinotecan
Sponsor: Abbott
Recruiting - verified February 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Methemoglobinemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm
Interventions: Drug: chemotherapy; Drug: dapsone; Other: medical chart review; Procedure: assessment of therapy complications
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

Condition: Lymphoblastic Leukemia, Acute, Childhood
Intervention: Drug: Clofarabine incorporated into a 5-drug regimen
Sponsor: Genzyme
Recruiting - verified October 2009
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Conditions: Lymphoma; Chronic Lymphocytic Leukemia; Solid Tumors
Interventions: Drug: ABT-263; Drug: ABT-263; Drug: ABT-263; Drug: ABT-263
Sponsors: Abbott; Genentech
Recruiting - verified December 2009
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Condition: Cancer
Interventions: Biological: adoptive immunotherapy; Biological: alemtuzumab; Biological: in vitro-treated peripheral blood lymphocyte therapy; Drug: foscarnet sodium; Drug: ganciclovir; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: infection prophylaxis and management; Procedure: peripheral blood stem cell transplantation; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsor: University Hospital Birmingham
Recruiting - verified September 2009
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma; Myelofibrosis; Anemia, Aplastic; Hemoglobinuria, Paroxysmal
Intervention: Drug: Basiliximab
Sponsor: Indiana University School of Medicine
Recruiting - verified March 2010
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Conditions: Leukemia; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; MDS; Multiple Myeloma
Interventions: Drug: EPOCH-F/R; Drug: FLAG; Drug: Transplant Preparative Regimen (Flu/Cy/Mes); Drug: GVHD Prophylaxis (tacrolimus and sirolimus); Procedure: Double Cord Blood Transplantation
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
Infusion of Expanded Cord Blood T Cells

Conditions: Stem Cell Transplantation; Leukemia; Lymphoma; Pediatrics
Interventions: Radiation: Total Body Irradiation (TBI); Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Rituximab; Drug: Etoposide; Drug: Anti-thymocyte globulin (ATG); Drug: Mycophenolate Mofetil (MMF); Drug: Tacrolimus; Procedure: Cord Blood Infusion; Drug: G-CSF; Procedure: Ex vivo expanded T cell Infusion
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Efficacy and Safety of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR™) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of functional alloreactive T-cells
Sponsor: Kiadis Pharma
Recruiting - verified March 2010
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm
Interventions: Biological: trivalent influenza vaccine; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: Influenza Vaccine Trivalent Inactivated (TIV); Drug: Pegylated interferon (PEGrIFN-α, Pegasys); Drug: Interferon (IFNα, Roferon-A)
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting - verified March 2010
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsor: Cancer Research UK
Recruiting - verified August 2009
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC; Drug: AZD1152 + LDAC
Sponsor: AstraZeneca
Recruiting - verified March 2010
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: everolimus; Drug: panobinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Viral Infection
Interventions: Other: cytology specimen collection procedure; Other: fluorescent antibody technique; Procedure: assessment of therapy complications
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2009
A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML)

Condition: Hematologic Malignancies
Interventions: Drug: PF-04449913; Drug: dasatinib
Sponsor: Pfizer
Recruiting - verified March 2010
Home Visits or Standard Therapy in Treating Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Psychosocial Effects of Cancer and Its Treatment; Therapy-related Toxicity
Interventions: Behavioral: exercise intervention; Behavioral: telephone-based intervention; Dietary Supplement: dietary intervention; Other: educational intervention; Other: questionnaire administration; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Procedure: peripheral blood stem cell transplantation; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Condition: Cancer
Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2010
Cyproheptadine Hydrochloride With or Without Nutritional Supplementation in Treating Young Patients With Weight Loss Caused by Cancer or Cancer Treatment

Conditions: Leukemia; Lymphoma; Malnutrition; Myelodysplastic Syndromes; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes
Interventions: Dietary Supplement: nutritional supplement drink; Dietary Supplement: nutritional supplement drink (pediatric); Drug: cyproheptadine hydrochloride
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Not yet recruiting - verified November 2009
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Dietary Supplement: CAM nutritional therapy; Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Not yet recruiting - verified July 2009
Controlling Blood Sugar Levels in Preventing Infection in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Conditions: Hyperglycemia; Leukemia
Interventions: Biological: insulin glargine recombinant; Drug: therapeutic insulin
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified July 2009
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: evaluation of cancer risk factors
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2009
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Conditions: Leukemia; Pediatrics
Interventions: Drug: Epratuzumab; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Mesna; Procedure: Infusion of NK cells; Drug: Interleukin-2
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Conditions: Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: obatoclax mesylate; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: 3'-deoxy-3'-[18F]fluorothymidine
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified September 2009
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC (low dose cytosine arabinoside)
Sponsor: AstraZeneca
Recruiting - verified March 2010
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Condition: Hairy Cell Leukemia
Intervention: Drug: BL22 (CAT-3888)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Condition: Leukemia-relapsed or Refractory
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Conditions: Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: Fludarabine Phosphate; Drug: Tacrolimus; Drug: Thiotepa; Radiation: Total-Body Irradiation (TBI); Device: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Sponsors: Yale University; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Conditions: Hematopoietic/Lymphoid Cancer; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; T-cell Adult Acute Lymphoblastic Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: panobinostat; Drug: everolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Other: flow cytometry; Other: immunohistochemistry staining method; Other: western blotting
Sponsor: Mayo Clinic
Recruiting - verified March 2010
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsor: Celgene Corporation
Recruiting - verified February 2010
A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Cytarabine in Patients With Acute Leukemias (Study P05247)

Conditions: Myelogenous Leukemia, Acute; Leukemia, Lymphocytic, Acute; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Myelogenous Leukemia, Chronic, Aggressive Phase
Interventions: Drug: SCH 900776; Drug: Cytarabine
Sponsor: Schering-Plough
Recruiting - verified March 2010
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Conditions: Advanced Myelodysplastic Syndrome; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia After MDS; Thrombocytopenia
Interventions: Drug: eltrombopag olamine; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood Samples From Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2008
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: proteomic profiling; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2008
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Studying Fentanyl in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fentanyl citrate; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib (Sprycel)
Sponsors: European Group for Blood and Marrow Transplantation; Bristol-Myers Squibb
Recruiting - verified March 2010
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

Condition: Cancer
Interventions: Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Procedure: allogeneic bone marrow transplantation
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

Conditions: Lymphoma; Small Intestine Cancer
Interventions: Procedure: radionuclide imaging; Procedure: single photon emission computed tomography; Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells; Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes
Sponsors: Holden Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2007
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Condition: Cancer
Interventions: Other: immunological diagnostic method; Other: physiologic testing
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Condition: Acute Myeloid Leukemia
Intervention: Drug: Fludarabine, Busulfan, Thymoglobulin
Sponsor: The Korean Society of Pediatric Hematology Oncology
Recruiting - verified February 2010
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias

Condition: Leukemia
Interventions: Drug: Etoposide, Mitoxantrone, Clofarabine; Drug: Clofarabine, Etoposide, Mitoxantrone
Sponsor: Penn State University
Recruiting - verified March 2010
Iron Overload in Patients Undergoing Donor Stem Cell Transplant

Condition: Cancer
Interventions: Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified August 2009
A Trial In Patients With Advanced Cancer And Leukemia

Conditions: Neoplasms by Histologic Type; Leukemia, Lymphoid; Leukemia, T-Cell; Solid Tumors
Intervention: Drug: PF-03084014
Sponsor: Pfizer
Recruiting - verified March 2010
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM5)

Conditions: Solid Tumors; Lymphoma, Non-Hodgkin; Multiple Myeloma; Leukemia, Lymphocytic, Chronic. B-Cell
Intervention: Drug: SCH 727965
Sponsor: Schering-Plough
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: FCR; Drug: BR
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Conditions: Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin; Drug: Vincristine; Drug: PEG-asparaginase; Drug: Intrathecal Methotrexate; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Doxorubicin; Drug: Thioguanine
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Observational Study of Nelarabine in Children and Young Adults

Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Intervention: Drug: nelarabine
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Sitagliptin Umbilical Cord Blood Transplant Study

Conditions: Leukemia, Myeloid, Acute; Acute Lymphoblastic Leukemia; Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin
Intervention: Drug: Sitagliptin
Sponsor: Indiana University School of Medicine
Recruiting - verified March 2010
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Condition: Hematologic Malignancies
Intervention: Drug: GSK21110183
Sponsor: Octagon Research Solutions, Inc.
Recruiting - verified February 2010
Growth Factor Signature (GFS) Pilot Study

Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia
Intervention: Other: Comparator: Biomarker evaluation
Sponsor: Merck
Recruiting - verified March 2010
Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Conditions: Chronic Myeloproliferative Disorders; Fanconi Anemia; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Paroxysmal Nocturnal Hemoglobinuria
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2009
Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Vincristine; Drug: Daunorubicin; Drug: Prednisone; Drug: Mitoxantrone; Drug: Cytosine Arabinoside; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: ASP; Drug: Mercaptopurine; Drug: Teniposide; Drug: Hydrocortisone
Sponsor: PETHEMA Foundation
Recruiting - verified March 2010
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Conditions: B-Cell Lymphoma; B-Cell Leukemia
Intervention: Drug: PCI-32765
Sponsor: Pharmacyclics
Recruiting - verified July 2009
Fludarabine, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded to Treatment

Condition: Leukemia
Interventions: Biological: bevacizumab; Biological: rituximab; Drug: fludarabine phosphate
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: 6-mercaptopurine, Methotrexate; Drug: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
Sponsor: Sun Yat-sen University
Recruiting - verified March 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: idarubicin; Drug: pravastatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2009
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsor: Asan Medical Center
Recruiting - verified July 2009
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: dasatinib; Drug: vorinostat; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Nonmalignant Neoplasm
Interventions: Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: protein analysis; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: reduced-intensity transplant conditioning procedure; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified July 2009
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Therapy-related Toxicity
Interventions: Biological: immunosuppressive therapy; Other: immunological diagnostic method; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
ABT-888 and Cyclophosphamide in Treating Patients With Solid Tumors or Lymphoma That Did Not Respond to Previous Therapy

Conditions: Leukemia; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ABT-888; Drug: cyclophosphamide; Other: immunologic technique; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)

Condition: AML
Intervention: Biological: AMLCTL
Sponsor: University of California, San Diego
Recruiting - verified January 2010
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Waldenstrom's Macroglobulinemia; Myelodysplastic Syndrome; Philadelphia Chromosome-negative CML; Myeloid Metaplasia; Myelofibrosis; Advanced Polycythemia; Non-Hodgkins Lymphoma
Intervention: Drug: TAK-901
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: therapeutic immune globulin; Drug: busulfan; Drug: fludarabine phosphate; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Institut Paoli-Calmettes
Recruiting - verified July 2009
Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin in CBF Leukemias

Condition: Acute Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Cytarabine; Drug: G-CSF (Filgrastim, Neupogen); Drug: Gemtuzumab Ozogamicin
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: intensity-modulated radiation therapy; Radiation: tomotherapy; Radiation: total marrow irradiation; Radiation: total nodal irradiation
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: alvocidib; Drug: cytarabine; Drug: mitoxantrone hydrochloride
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: sirolimus; Drug: tacrolimus; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Stem Cell Transplant Cope With Late Complications

Condition: Cancer
Interventions: Other: internet-based intervention; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: fatigue assessment and management; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Natural Killer Cells and Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: natural killer cell therapy; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Early Administration of Antithymocyte Globulin Followed By Cyclophosphamide, Busulfan, and Fludarabine Before a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Kidney Cancer

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Genetic: polymerase chain reaction; Other: pharmacological study; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsor: Blood and Marrow Transplant Group of Georgia
Recruiting - verified June 2009
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sarcoma
Interventions: Other: educational intervention; Other: informational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Tufts Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsor: Northside Hospital, Inc.
Recruiting - verified March 2010
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Conditions: Chronic Myeloproliferative Disorders; Depression; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: medical chart review; Other: questionnaire administration; Procedure: psychosocial assessment and care
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2008
Hydroxychloroquine in Untreated B-CLL Patients

Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Drug: Hydroxychloroquine
Sponsor: North Shore Long Island Jewish Health System
Recruiting - verified March 2010
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell
Intervention: Drug: AEG35156 antisense IV infusion
Sponsors: Aegera Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified March 2010
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Condition: Cancer
Interventions: Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes; Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Biological: therapeutic allogeneic lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunological diagnostic method; Other: laboratory biomarker analysis
Sponsors: Milton S. Hershey Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2008
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Lymphoma; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic
Intervention: Drug: azacitidine
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Phase I/IIa Trial to Investigate BI 6727 as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: BI 6727 (d1 and 15); Drug: BI 6727 (d1 and 15); Drug: Cytarabine; Drug: Cytarabine
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclosporine ophthalmic emulsion; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Trial Of Double Umbilical Cord Blood Transplantation

Condition: Hematological Malignancies
Interventions: Procedure: full intensity, double umbilical cord, stem cell transplant; Drug: Flu/Bu4 conditioning regimen; Radiation: Total Lymphoid Irradiation (TLI); Drug: Graft versus Host Disease prevention (GVHD prophylaxis)
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer

Conditions: Brain Tumors; Leukemia; Sarcomas; Neuroblastoma; Lymphoma; Hodgkins Disease
Interventions: Other: Aromatherapy Scented Wand; Other: Placebo wand
Sponsors: Montefiore Medical Center; Soothing Scents, Inc.
Recruiting - verified March 2010
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Stem Cell Transplantation
Intervention: Drug: Nilotinib
Sponsor: Sheba Medical Center
Recruiting - verified March 2010
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia

Conditions: Leukemia; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Aurora A kinase inhibitor MLN8237; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: chlorambucil
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methadone hydrochloride; Drug: morphine sulfate; Drug: oxycodone hydrochloride
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Non-Hodgkins Lymphoma; Sarcoma; Neuroblastoma
Intervention: Other: FDA Food Safety Guidelines
Sponsor: Montefiore Medical Center
Recruiting - verified March 2010
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: panobinostat; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
American Ginseng in Treating Patients With Fatigue Caused by Cancer

Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Condition: Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Interventions: Drug: Daunorubicin and Cytarabine; Drug: Amonafide and Cytarabine
Sponsor: Antisoma Research
Recruiting - verified March 2010
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

Conditions: Lymphoma; Hodgkin Disease; Lymphoma, Non-Hodgkin
Intervention: Drug: PCI-24781
Sponsor: Pharmacyclics
Recruiting - verified December 2009
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Condition: Graft Versus Host Disease
Interventions: Drug: Visilizumab; Drug: Tacrolimus; Drug: Methotrexate; Drug: Antithymocyte globulin (ATG); Drug: Tacrolimus; Drug: Methotrexate
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Institutes of Health (NIH)
Recruiting - verified March 2010
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; Genzyme; National Institutes of Health (NIH)
Recruiting - verified February 2010
Imatinib Mesylate in Treating Patients With Sclerodermatous Chronic Graft-Versus-Host Disease

Condition: Cancer
Interventions: Drug: imatinib mesylate; Genetic: reverse transcriptase-polymerase chain reaction; Other: confocal microscopy; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: biopsy
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: rituximab; Drug: busulfan; Drug: carmustine; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia Patients With Low MGMT Expression (Study P05052)

Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome.

Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: JNJ-26481585.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Conditions: Adrenocortical Carcinoma; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab; Drug: temsirolimus
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
EZN-2285 or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: acupressure therapy; Procedure: biopsy; Procedure: bone marrow aspiration; Procedure: pain therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Pazopanib in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Conditions: Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cytotoxic T Cells in Treating Patients With Relapsed Epstein-Barr Virus-Positive Lymphoma

Conditions: Head and Neck Cancer; Lymphoma; Lymphoproliferative Disorder; Nonneoplastic Condition; Small Intestine Cancer
Intervention: Biological: TGF-beta-resistant LMP-specific cytotoxic T-lymphocytes
Sponsors: Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified June 2009
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: educational intervention; Other: medical chart review; Other: questionnaire administration; Procedure: pain therapy; Procedure: quality-of-life assessment
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2009
Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Conditions: Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma
Intervention: Drug: CAT-8015
Sponsors: MedImmune LLC; National Cancer Institute (NCI)
Recruiting - verified March 2010
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Montelukast in Treating Patients With Bronchiolitis Obliterans After Stem Cell Transplant

Condition: Cancer
Interventions: Drug: montelukast sodium; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2008
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Conditions: Solid Tumor Malignancy; Lymphoid Malignancy (Lymphoma and CLL); Leukemia; Lymphoma
Intervention: Drug: SNX-5422 Mesylate Hsp90 inhibitor
Sponsors: Pfizer; National Cancer Institute (NCI)
Recruiting - verified March 2010
SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment

Conditions: Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Hsp90 inhibitor SNX-5422 mesylate; Other: flow cytometry; Other: high performance liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Condition: Chronic Myelogenous Leukemia - Chronic Phase
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: BI 811285 (d 1 and 15); Drug: BI 811283 (d1); Drug: Cytarabine; Drug: Cytarabine; Drug: Cytarabine
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Baylor College of Medicine
Recruiting - verified June 2009
A Study of R7112 in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RG7112
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

Condition: Acute Myelogenous Leukemia
Interventions: Drug: Fludarabine, Busulfan (FluBu2); Drug: Fludarabine, Busulfan (FluBu4); Radiation: total body irradiation; Procedure: stem cell transplant
Sponsor: University of Michigan Cancer Center
Recruiting - verified October 2009
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Condition: Cancer
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: rituximab; Drug: clofarabine; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
A Phase 1/2 Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: TRU-016 (anti-CD37 protein therapeutic)
Sponsor: Trubion Pharmaceuticals
Recruiting - verified March 2010
Phase II Temozolomide in Acute Myeloid Leukemia Patient Age >= 60 Yrs & Poor Risk/Refractory Disease

Condition: Leukemia, Myeloid
Intervention: Drug: Tailored Temozolomide therapy
Sponsors: Stanford University; Schering-Plough
Recruiting - verified March 2010
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
Stem Cell Transplantation To Treat High Risk Lymphoid Diseases With Reduced Toxicity Myeloablative Conditioning Regimen

Conditions: Multiple Myeloma; Plasma Cell Leukemia; Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days; Procedure: stem cell transplant
Sponsors: University of Michigan Cancer Center; PDL BioPharma, Inc.
Recruiting - verified March 2010
T Lymphocytes in Treating Patients Undergoing a Donor Bone Marrow Transplant

Condition: Cancer
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: immunological diagnostic method; Procedure: adjuvant therapy
Sponsor: Baylor College of Medicine
Recruiting - verified June 2009
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: etoposide; Drug: tipifarnib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Conditions: Liver Cancer; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dasatinib; Other: pharmacological study
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia
Interventions: Radiation: Total Body Irradiation; Drug: Thiotepa; Drug: Fludarabine; Biological: Rabbit ATG; Drug: Palifermin
Sponsor: Indiana University
Recruiting - verified January 2010
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

Conditions: Cancer; Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Interventions: Drug: Fludarabine, Cyclophosphamide; Procedure: Transplantation
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia

Condition: Hairy Cell Leukemia
Intervention: Biological: CAT 8015
Sponsors: MedImmune LLC; Cambridge Antibody Technology
Recruiting - verified March 2010
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Secondary Myelofibrosis; Small Intestine Cancer
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
ABT-888 and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: ABT-888; Drug: carboplatin; Drug: topotecan hydrochloride; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Combination of Imatinib Mesylate and Pegylated Interferon α2a in Chronic-Phase Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Intervention: Drug: PEG-IFN-a2a
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Studying Patients With a Personal or Family History of Cancer Caused by a Virus

Conditions: Lymphoma; Lymphoproliferative Disorder; Sarcoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: biologic sample preservation procedure; Other: cytology specimen collection procedure; Other: immunologic technique; Procedure: biopsy; Procedure: study of high risk factors
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2009
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Intervention: Drug: asparaginase-Erwinia
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Conditions: Childhood Germ Cell Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Neuroblastoma; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: carboplatin; Drug: carmustine; Drug: cyclophosphamide; Drug: etoposide; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Biological: rituximab; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: prednisone; Drug: sirolimus; Drug: tacrolimus; Drug: vincristine sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: etoposide; Drug: methotrexate; Drug: rasburicase; Drug: sirolimus; Drug: tacrolimus; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsor: Massachusetts General Hospital
Recruiting - verified April 2008
Aflibercept in Treating Patients With Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: aflibercept; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunoenzyme technique; Other: immunologic technique; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2009
Adult Double Cord Blood Transplant Study

Conditions: Cord Blood Stem Cell Transplantation; Hematologic Malignancies
Intervention: Procedure: Cord blood transplantation
Sponsor: Center for International Blood and Marrow Transplant Research
Recruiting - verified March 2010
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Condition: Cancer
Interventions: Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsor: Milton S. Hershey Medical Center
Recruiting - verified October 2007
Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Conditions: Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat; Other: pharmacological study
Sponsors: University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified July 2009
Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treosulfan-based Conditioning for Transplantation in AML/MDS

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Interventions: Drug: treosulfan; Drug: Treosulfan
Sponsor: Sheba Medical Center
Recruiting - verified March 2010
Beclomethasone in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: beclomethasone dipropionate; Drug: methotrexate; Drug: tacrolimus; Other: placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

Conditions: Myelodysplastic Syndromes; MDS
Intervention: Drug: Gimatecan
Sponsors: M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2010
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: ABT-263
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Conditions: Richter's Transformation; Leukemia
Interventions: Drug: Oxaliplatin; Drug: Fludarabine; Drug: Cytarabine; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; Sanofi-Aventis
Recruiting - verified March 2010
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia
Interventions: Drug: Clofarabine; Drug: Busulfan; Drug: Fludarabine
Sponsors: M.D. Anderson Cancer Center; Genzyme
Recruiting - verified March 2010
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndrome; Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Busulfan; Drug: Fludarabine
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: sargramostim; Drug: entinostat; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: flow cytometry
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

Condition: Cancer
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsor: St. Bartholomew's Hospital
Recruiting - verified September 2007
Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab; Drug: cediranib maleate; Genetic: TdT-mediated dUTP nick end labeling assay; Other: flow cytometry; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: graft-versus-tumor induction therapy; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: fludarabine phosphate; Drug: melphalan; Drug: methotrexate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
A Study of Actonel for the Prevention of Bone Loss

Conditions: Leukemia; Lymphoma
Interventions: Drug: Actonel (Risedronate); Dietary Supplement: Calcium; Dietary Supplement: Vitamin D
Sponsors: M.D. Anderson Cancer Center; Procter and Gamble
Recruiting - verified March 2010
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2008
Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Biological: sargramostim; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2008
Batracylin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

Conditions: Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: daniquidone; Other: pharmacological study
Sponsor: National Cancer Institute (NCI)
Recruiting - verified June 2009
Education Sessions for Young Relative Stem Cell Donors

Condition: Cancer
Interventions: Other: counseling intervention; Other: educational intervention; Procedure: psychosocial assessment and care
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2008
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia

Conditions: Lymphoma; Neutropenia; Psychosocial Effects of Cancer and Its Treatment; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: amoxicillin-clavulanate potassium; Drug: ciprofloxacin; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsor: Clatterbridge Centre for Oncology
Recruiting - verified May 2007
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Conditions: Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer
Interventions: Drug: everolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified October 2009
Cellular Therapy With Cord Blood Cells

Conditions: Multiple Myeloma; Leukemia; Lymphoma
Interventions: Drug: Fludarabine; Drug: Melphalan; Procedure: Umbilical Cord Blood; Drug: Rituximab; Other: Peripheral Blood Stem Cell Infusion
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: sargramostim; Drug: bexarotene; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; AML
Interventions: Drug: Cytarabine; Drug: Idarubicin
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pemetrexed disodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsor: Robert H. Lurie Cancer Center
Recruiting - verified July 2009
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: busulfan; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Drug: etoposide; Genetic: cytogenetic analysis; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia; Leukemia
Intervention: Drug: 5-Azacytidine
Sponsors: M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified March 2010
All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab and Theophylline

Condition: Acute Promyelocytic Leukemia
Interventions: Drug: All-Trans Retinoic Acid (ATRA); Drug: Arsenic Trioxide (ATO); Drug: Gemtuzumab Ozogamicin (GO); Drug: Theophylline
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

Conditions: Burkitt's Lymphoma; Lymphoblastic Lymphoma; Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; Genzyme
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lithium in Treating Patients With Acute Intestinal Graft-Versus-Host Disease After Donor Stem Cell Transplant

Condition: Cancer
Intervention: Drug: lithium carbonate
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

Conditions: Leukemia; Long-term Effects Secondary to Cancer Therapy in Adults; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Sexual Dysfunction and Infertility; Sexuality and Reproductive Issues; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Procedure: fertility assessment and management; Procedure: management of therapy complications; Procedure: ultrasound imaging
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Secondary Myelofibrosis; Small Intestine Cancer
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: in vitro-treated peripheral blood stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009
Fludarabine and Total-Body Irradiation Followed By a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Secondary Myelofibrosis
Interventions: Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL

Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2010
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Conditions: Chronic Myeloproliferative Disorders; Leukemia
Interventions: Drug: fludarabine phosphate; Drug: triapine; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: methotrexate; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients Receiving Vincristine for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma

Conditions: Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma
Interventions: Dietary Supplement: glutamic acid; Other: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); Children's Oncology Group
Recruiting - verified February 2010
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

Conditions: Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma
Interventions: Dietary Supplement: glutamine; Other: placebo
Sponsor: Herbert Irving Comprehensive Cancer Center
Recruiting - verified December 2008
Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: GM-K562 cell vaccine; Biological: recombinant interferon alfa; Biological: sargramostim
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cytarabine; Drug: etoposide; Drug: vorinostat; Genetic: microarray analysis; Genetic: protein expression analysis; Other: pharmacological study
Sponsors: University of Maryland Greenebaum Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Cyclophosphamide and Donor Lymphocytes in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: donor lymphocytes; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Intervention: Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: azacitidine; Drug: belinostat
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2009
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: carboplatin; Drug: carmustine; Drug: cyclophosphamide; Drug: etoposide; Drug: ifosfamide; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified July 2009
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Conditions: Lymphoma; Lymphoproliferative Disorder; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: belinostat; Drug: bortezomib; Other: pharmacological study
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified October 2007
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Conditions: Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: sorafenib tosylate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Umbilical Cord Blood Stem Cell Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer and Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant

Condition: Cancer
Interventions: Other: laboratory biomarker analysis; Other: physiologic testing; Procedure: biopsy; Procedure: management of therapy complications
Sponsor: National Cancer Institute (NCI)
Recruiting - verified September 2006
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: moxifloxacin hydrochloride
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Osteoporosis; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: cholecalciferol; Drug: calcium gluconate; Drug: zoledronic acid
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Conditions: Kidney Cancer; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Pulmonary Complications; Sarcoma
Interventions: Biological: etanercept; Drug: methylprednisolone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: CD4+CD25+ regulatory T cells; Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified September 2009
Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant

Condition: Cancer
Interventions: Procedure: music therapy; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: clofarabine; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Conditions: Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gemcitabine hydrochloride; Drug: triapine
Sponsors: Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2007
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unusual Cancers of Childhood
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: carmustine; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methotrexate; Drug: methylprednisolone; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2007
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Drug: mercaptopurine; Drug: methotrexate; Other: study of socioeconomic and demographic variables
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: asparaginase; Drug: dexamethasone; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: graft-versus-tumor induction therapy; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsor: James P. Wilmot Cancer Center
Recruiting - verified June 2007
Study of Dasatinib in Patients With Chronic Myelogenous Leukemia

Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib (BMS-354825)
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2010
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2009
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Conditions: Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Stem Cell Transplant for Hematological Malignancy

Conditions: Leukemia, Myeloid, Chronic; AML; Leukemia, Lymphocytic, Acute; MDS; Leukemia, Lymphocytic, Chronic; JMML; Hodgkin's Disease; Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide; Radiation: Total Body Irradiation; Drug: Busulfan
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone; Drug: methotrexate, teniposide, PEG-asparaginase; Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine; Drug: L-asparaginase, erwinia asparaginase; Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy; Procedure: Hematopoietic Stem Cell Transplant; Procedure: Natural Killer (NK) Cell Transplant
Sponsor: St. Jude Children's Research Hospital
Recruiting - verified March 2010
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: bone marrow ablation with stem cell support
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Radiation: radiation therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Condition: Leukemia, Myelogenous, Chronic
Intervention: Drug: Nilotinib
Sponsors: M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2010
Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: alemtuzumab; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Carcinoma of Unknown Primary; Leukemia; Lymphoma; Metastatic Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: topotecan hydrochloride
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2008
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Condition: Cancer
Intervention: Drug: caspofungin acetate
Sponsor: European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: fenretinide
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: epratuzumab; Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: graft-versus-tumor induction therapy; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Study of Late-Occurring Complications in Childhood Cancer Survivors

Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: filgrastim; Biological: graft-versus-tumor induction therapy; Biological: rituximab; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: prednisone; Drug: vincristine sulfate; Procedure: peripheral blood stem cell transplantation
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: sirolimus
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2007
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: pentostatin
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Randomized Double Cord Blood Transplant Study

Conditions: Leukemia, Lymphocytic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Chronic; Lymphoma, Non-Hodgkin
Interventions: Procedure: Expanded allogeneic cord blood (CB); Procedure: One Unmanipulated and One Expanded Cord Blood Unit
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: graft-versus-tumor induction therapy; Biological: sargramostim; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: umbilical cord blood transplantation; Drug: methylprednisolone
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Other: laboratory biomarker analysis; Genetic: gene expression analysis; Other: immunologic technique; Other: flow cytometry; Genetic: polymerase chain reaction; Genetic: cytogenetic analysis; Other: staining method
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Screening Individuals and Families at High Risk for Hematologic Cancers

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: genetic linkage analysis; Genetic: microarray analysis; Other: counseling intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: evaluation of cancer risk factors
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2007
Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: etoposide; Drug: imatinib mesylate; Drug: methotrexate; Drug: tacrolimus; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Oral Complications; Ovarian Cancer; Pain; Sarcoma
Interventions: Procedure: management of therapy complications; Procedure: pain therapy
Sponsor: Medical College of Wisconsin
Recruiting - verified June 2009
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation
Sponsor: Roswell Park Cancer Institute
Recruiting - verified June 2009
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Conditions: Graft vs Host Disease; Healthy; Lymphopenia
Intervention: Drug: G-CSF
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2009

Find Clinical Trials for Leukemia - Clinical Trials

Find Clinical Trials for Leukemia

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials